Regular Article
The Tyrosine Kinase Inhibitor, Genistein, Prevents α-Adrenergic-Induced Cardiac Muscle Cell Hypertrophy by Inhibiting Activation of the Ras-MAP Kinase Signaling Pathway

https://doi.org/10.1006/bbrc.1994.2113Get rights and content

Abstract

The α-adrenergic agonist, phenylephrine, has been widely used to induce hypertrophy in cultured ventricular myocytes from neonatal rats. We have investigated the role of tyrosine phosphorylation in this signaling pathway using the tyrosine kinase inhibitor, genistein. We find that genistein treatment prevents phenylephrine-induced activation of three promoters (Fos, atrial natriuretic factor, ANF, and the myosin light chain 2, MLC-2), which are activated in the hypertrophic response. Genistein also inhibits phenylephrine-induced activation of the mitogen activated protein (MAP) kinases Erk1 and Erk2 and inhibits GTP loading of the Ras protein. These data demonstrate that a genistein-sensitive step is critical for the activation of the Ras-MAP kinase pathway by phenylephrine and suggest that this pathway is important in the regulation of the hypertrophic response.

References (0)

Cited by (77)

  • The Pathophysiology of Cardiac Hypertrophy and Heart Failure

    2014, Cellular and Molecular Pathobiology of Cardiovascular Disease
  • Regulation of telomerase activity by apparently opposing elements

    2010, Ageing Research Reviews
    Citation Excerpt :

    Genistein, a natural isoflavone similar to estrogen and present in soybean, has been shown to inhibit a number of cancers, including prostate cancer (Alhasan et al., 2001; El Touny and Banerjee, 2009; Majid et al., 2008). Genistein inhibits epidermal growth factor receptor tyrosine kinase (Akiyama et al., 1987; Markovits et al., 1989; Thorburn and Thorburn, 1994), inhibits DNA topoisomerase II in Chinese hamster lung cells (Markovits et al., 1989) and induces p21WAF1/CIP1 and p16INK4a tumor suppressor genes in prostate cancer cells (Majid et al., 2008; Rao et al., 2004). In addition, genistein has been shown to inhibit telomerase in prostate cancer (Chau et al., 2007; Jagadeesh et al., 2006; Ouchi et al., 2005) and breast cancer (Li et al., 2009).

  • S1P<inf>1</inf> receptor localization confers selectivity for G <inf>i</inf>-mediated cAMP and contractile responses

    2008, Journal of Biological Chemistry
    Citation Excerpt :

    One possible explanation is that different Gi subunits mediate these responses. Inhibition of the major isoforms of adenylyl cyclase in the heart (ACV/VI) is known to be mediated by the α subunit of Gi (47), whereas activation of MAP kinases and Akt is thought to occur through β/γ subunits (32, 48–51). One might speculate that β/γ subunits released when Gi is activated through the caveolar S1P1 receptor are unable to access the signaling molecules (e.g. phosphatidylinositol 3-kinase and Ras) that ultimately activate Akt and ERK.

View all citing articles on Scopus
View full text